TFF Pharmaceuticals (TFFP)
(Real Time Quote from BATS)
$2.02 USD
-0.29 (-12.55%)
Updated Sep 23, 2024 03:42 PM ET
2-Buy of 5 2
F Value B Growth F Momentum F VGM
Brokerage Reports
0 items in cart
TFF Pharmaceuticals, Inc. [TFFP]
Reports for Purchase
Showing records 1 - 20 ( 153 total )
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Preclin Bivalent Intranasal Universal Flu Vaccines Elicit Neutralizing Abs
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q24: Expecting Clarification of Next Clinical Steps for TFF TAC by YE24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Continued Positive TFF TAC Data In Preventing Lung Transplant Rejection
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q24: Updated TFF TAC Data Adds To Earlier Promising Phase 2 Results
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive TFF TAC Biomarker Data Shown at ISHLT, Lower Systemic Exposure
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q23: TFF TAC Data Support Phase 3 Trial, Looking To Outlicense TFF VORI
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New TFF TAC Data Supports Phase 3 Trial, Looking To Outlicense TFF VORI
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - 36th Annual Roth Conference, Biotechnology Track, March 17-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Preliminary Phase 2 TFF VORI TFF TAC Results, Trials Continue
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q23: Funded Beyond Release Of Potentially Transformational Phase 2 Data
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q23: Funded Beyond Release Of Potentially Transformational Phase 2 Data
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Opens TFF VORI Expanded Access Program With Uniphar Durbin Ireland Ltd.
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: TFF Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Receives Validating $3 Million SBIR Grant For Universal Influenza Vaccine
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J